Get the Stockscreener App
1.46
2.99%
-0.045
After Hours:
1.49
0.03
+2.05%
Milestone Pharmaceuticals Inc stock is traded at $1.46, with a volume of 1.28M.
It is down -2.99% in the last 24 hours and down -30.48% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$1.505
Open:
$1.53
24h Volume:
1.28M
Relative Volume:
0.64
Market Cap:
$174.67M
Revenue:
$1.55M
Net Income/Loss:
$-63.06M
P/E Ratio:
-1.8344
EPS:
-0.7959
Net Cash Flow:
$-49.45M
1W Performance:
-23.16%
1M Performance:
-30.48%
6M Performance:
-39.42%
1Y Performance:
+19.67%
1-Day Range:
$1.46
$1.56
1-Week Range:
$1.46
$1.97
52-Week Range:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.46 | 180.05M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Raises Target Price to $7 - Moomoo
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highl - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals Files $300 Million Mixed Shelf - Moomoo
Why Milestone Pharmaceuticals Stock Wilted on Wednesday - The Motley Fool
Milestone Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $6.33, Implies 233% Upside - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Milestone Pharmaceuticals Inc. may issue and sell common shares worth up to 100 million dollars through an equity distribution sales agreement with Cantor Fitzgeral - Bitget
Milestone Pharmaceuticals IncMay offer securities up to $300 millionSEC filing - marketscreener.com
Milestone Pharmaceuticals (NASDAQ: MIST) files $300M shelf; $100M ATM with Cantor Fitzgerald - Stock Titan
Q1 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results - MarketBeat
Milestone Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals (MIST) Reports Q1 Earnings Miss - GuruFocus
Milestone Pharmaceuticals (MIST) Q1 2026 Earnings: EPS and Reven - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Milestone Pharmaceuticals (MIST) Reports Strong Q1 Revenue Growt - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales - Benzinga
Earnings call transcript: Milestone Pharmaceuticals Q1 2026 misses forecasts, stock drops - Investing.com
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Yahoo Finance
Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST) - Yahoo Finance
Adage (MIST) holds 8,000,000 warrant-derived shares, 6.37% - Stock Titan
Milestone Shares Fall on Unexpected 1Q Loss - Moomoo
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals earnings missed by $0.43, revenue fell short of estimates - Investing.com Canada
Milestone Pharmaceuticals stock tumbles 16% on revenue miss By Investing.com - Investing.com India
Milestone Pharmaceuticals reports Q1 2026: $0.2M product revenue, $26.1M net loss, $184.2M cash - TradingView
Milestone Pharmaceuticals stock tumbles 16% on revenue miss - Investing.com
Canada's Milestone Pharmaceuticals Q1 revenue misses estimates after CARDAMYST launch - TradingView
Milestone Pharmaceuticals Reports Progress on CARDAMYST™ Launch and Financial Performance for Q1 2026 - Quiver Quantitative
Milestone Pharmaceuticals: Q1 Earnings Snapshot - standard-journal.com
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance Singapore
Milestone Pharmaceuticals (NASDAQ: MIST) posts first CARDAMYST sales and boosts cash with royalty deal - Stock Titan
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):